PAVmed stockholders approve 4x increase in authorized shares to 250M and Series C Preferred issuance

PAVmed Inc.

Stockholders approved amending the certificate of incorporation to increase authorized common shares from 50M to 250M, effective Jan 15, 2025.
Stockholders also approved the issuance of common stock upon conversion of Series C Convertible Preferred shares.
Series C Preferred will be issued under a Debt Exchange Agreement and a Securities Purchase Agreement, both dated November 2024.
Company expects to consummate the Series C Preferred issuance and debt exchange by January 31, 2025.
Vote tallies: For amendment 5.23M vs 0.72M against; for issuance 5.48M vs 0.46M against.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

PAVmed Inc.: Amendment to increase authorized common stock from 50 million to 250 million shares (effective 2025-01-15).

Change: charter amendment
Effective: 2025-01-15

Exact text from the filing

A proposal to approve an amendment to the Company’s certificate of incorporation, as amended (the “ Certificate of Incorporation ”), to increase the total number of shares of common stock the Company is authorized to issue by 200,000,000 shares, from 50,000,000 shares to 250,000,000 shares.

View on SEC.gov

Browse all governance changes →

PAVmed Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-002398

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.